Research into therapeutically targeting the CDK4 pathway in a subset of ESS patients shows promise, indicating that alterations in this pathway, for which targeted therapies are available, may contribute to the pathogenesis of BCOR-rearranged ESS. This evidence concerns the gene CDK4 and endometrioid stromal sarcoma.